---
search:
  boost: .9
---

# Aldara

**actinic keratosis**

[Criteria Document](https://mygainwell-my.sharepoint.com/:w:/g/personal/kaelyn_dobbins_gainwelltechnologies_com/EU6Msw2o-F1Kixt7BJ6kGY0BJyCzEpNDK3bIXpXkmhIPjA?e=g56vLd){:target="_blank" rel="noopener}

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Topical agents for Actinic Keratosis</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Aldara (imiquimod)</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>ALDARA</td>
<td>031099</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th>Sequence Number</th>
<th>Question ID</th>
<th>Default Next Question ID</th>
<th>Question Type</th>
<th>Question Text</th>
<th>Choice Text</th>
<th>Next Question ID</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>1000</td>
<td></td>
<td>Select</td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?</td>
<td>Y</td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>2</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response to generic imiquimod 5%?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>3</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td>What is the patient’s diagnosis?  </td>
<td>Actinic keratosis</td>
<td>2000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Superficial basal cell carcinoma</td>
<td>3000</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genital or perianal warts</td>
<td>4000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>2000</td>
<td></td>
<td>Select</td>
<td><p>Ohio Medicaid covers up to 36 single-use packets in a 16-week period for actinic keratosis.</p>
<p>Does this request meet this requirement?</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1236</td>
</tr>
<tr class="odd">
<td>5</td>
<td>3000</td>
<td></td>
<td>Select</td>
<td><p>Ohio Medicaid covers up to 36 single-use packets in a 6-week period for superficial basal cell carcinoma.</p>
<p>Does this request meet this requirement?</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1236</td>
</tr>
<tr class="odd">
<td>6</td>
<td>4000</td>
<td></td>
<td>Select</td>
<td><p>Ohio Medicaid covers up to 48 single-use packets in a 16-week period for genital or perianal warts.</p>
<p>Does this request meet this requirement?</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1236</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>8</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the dose and frequency being requested.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATION: Actinic keratosis- 16 weeks; Superficial basal cell carcinoma-6 weeks; Genital or perianal warts- 16 weeks

|||
| ------------------ | -------- |
| **Last Approved ** | 5/1/2023 |
| **Other**          |          |
